Apellis Pharmaceuticals, Inc.·4

Sep 2, 10:13 AM ET

MELTZER LESLIE 4

4 · Apellis Pharmaceuticals, Inc. · Filed Sep 2, 2025

Insider Transaction Report

Form 4
Period: 2025-08-26
MELTZER LESLIE
Chief Research and Development
Transactions
  • Award

    Common Stock

    2025-08-26+61,80461,804 total
  • Award

    Stock Option (Right to Buy)

    2025-08-26+92,59292,592 total
    Exercise: $16.20Exp: 2035-08-26Common Stock (92,592 underlying)
Footnotes (2)
  • [F1]This restricted stock unit was granted on August 26, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
  • [F2]This represents a stock option award granted August 26, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT